Stimulus-responsive nanocapsule for delivering PROTAC, and preparation method and application thereof

By designing PROTAC-containing stimulus-responsive nanocapsules with PEG-polyamino acid polymers, the use of disulfide bond groups to release drugs in the hyperglutathione environment, solving the problem of DNA damage repair in brain glioma treatment. Targeted delivery of nanocapsules and on-demand drug release are achieved, improving the effectiveness of glioma treatment.

CN118903052AActive Publication Date: 2024-11-08FUDAN UNIVERSITY
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202411372774.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-29
Publication Date
2024-11-08
Estimated Expiration
2044-09-29

AI Technical Summary

Technical Problem

Brain glioma has the ability to repair DNA damage, the existing therapies are not effective, and the molecular weight, solubility and permeability of PROTAC are difficult to effectively deliver to the brain, resulting in treatment difficulties.

Method used

Design a stimulus-responsive nanocapsule that uses PEG-polyamino acid polymer to carry PROTAC drugs and releases drugs in a hyperglutathione environment through disulfide bond groups, combining GSH stimulus responsiveness and L-type amino acid transport Somatospecific recognition enables targeted delivery and on-demand drug release.

Benefits of technology

The biocompatibility and stability of nanocapsules are achieved, and can target brain glioma lesions, enhance DNA damage effect, improve the clinical efficacy of radiotherapy and chemotherapy, and overcome the shortcomings of existing anti-glioma therapies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903052A_ABST
    Figure CN118903052A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of pharmaceutical preparations, and relates to a stimulus-responsive nanocapsule for delivering PROTAC as well as a preparation method and application of the stimulus-responsive nanocapsule. According to the invention, firstly, a tryptophan analogue coupling compound is added into a nanocapsule drug loading system, so that the effect of a glioma focus specific targeting ligand can be exerted; secondly, a disulfide bond group is introduced into the nanocapsule, so that the in-tumor high glutathione response function of the nanocapsule can be exerted; besides, under the action of high glutathione, the nanocapsule can release the PROTAC medicine, the curative effects of efficiently degrading protein and inhibiting tumor cells are achieved, and meanwhile, due to the fact that a large amount of glutathione is consumed, oxidative stress is enhanced, and the effect of active oxygen damaging DNA is promoted. The nanocapsule prepared by the invention has GSH stimulation responsiveness and L-type amino acid transporter 1 specific recognition and phagocytic ability, can overcome the defects of the existing anti-glioma therapy, realizes glioma focus targeted accumulation and on-demand drug release, and enhances the clinical effects of the existing glioma radiotherapy and chemotherapy.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of pharmaceutical preparations and relates to a stimuli-responsive nanocapsule for delivering PROTAC, a preparation method and an application thereof. Background Art

[0002] Gliomas are the most common primary malignant brain tumors, with a five-year survival rate of less than 5%. Single therapy is not enough to inhibit its occurrence and development. Clinically, a combination of radiotherapy and chemotherapy is generally used to prolong patient survival. Radiotherapy uses high-energy rays including X-rays to damage DNA, and chemotherapy uses the DNA alkylating agent temozolomide. It can be concluded that DNA damage is the main means of clinical treatment of gliomas; however, the current clinical efficacy is not good, and the main reason is that gliomas have the ability to repair damaged DNA. Therefore, the key point of glioma treatment is to inhibit DNA damage repair.

[0003] Studies have shown that the key protein for DNA damage repair is BRD4, which is an epigenetic regulator that is highly expressed in brain gliomas. Therefore, targeting BRD4 is expected to become a potential sensitization method for glioma treatment. However, BRD4 lacks small molecule inhibitors and is a traditionally undruggable protein. Different from the occupancy inhibition principle of small molecule inhibitors, PROTAC can efficiently degrade "undruggable" target proteins by ubiquitination tagging target proteins.

[0004] However, PROTAC has the characteristics of large molecular weight, poor solubility and permeability, and faces the problem of difficulty in entering the brain, which requires the design of an intelligent drug delivery system to improve it. Therefore, how to match the treatment dilemma of brain glioma and combine the tumor microenvironment to achieve efficient DNA damage is a key scientific issue in clinical treatment; using an intelligent drug delivery system to deliver PROTAC to enhance the DNA damage effect is one of the key strategies for clinical sensitization of radiotherapy and chemotherapy. Summary of the invention

[0005] In order to solve the above technical problems, the present invention provides a stimulus-responsive nanocapsule for delivering PROTAC and a preparation method. Under the premise of fully considering the relevant pathological factors of brain glioma (including high concentration of glutathione), the present invention first selects a PROTAC drug with high efficiency in degrading the target protein BRD4; then synthesizes a high molecular polymer based on PEG-polyamino acid, couples PEG with tryptophan analogs through click reaction, and polymerizes with amino acids to obtain a high molecular polymer with high biocompatibility; uses an amphiphilic polymer to encapsulate the hydrophobic PROTAC drug into the nanoparticle core, and then uses a cross-linking reaction to form a nanocapsule, enhances the stability of the overall preparation, and gives it lesion response performance.

[0006] The present invention first adds the tryptophan analogue coupling compound to the nanocapsule drug delivery system, which can play the role of its glioma lesion-specific targeting ligand; secondly, because the disulfide bond has a glutathione response function, the disulfide bond group is introduced into the nanocapsule, which can play its intratumoral high glutathione response function; in addition, under the action of high glutathione, the nanocapsule can release PROTAC drugs, play the effect of efficient protein degradation and tumor cell inhibition, and at the same time, due to the large consumption of glutathione, it enhances oxidative stress and promotes the role of reactive oxygen damaging DNA. Therefore, the nanocapsule prepared by the present invention has both GSH stimulus responsiveness, L-type amino acid transporter 1 specific recognition and phagocytic ability, can overcome the shortcomings of existing anti-glioma therapies, and achieve targeted accumulation of glioma lesions, on-demand drug release, and enhance the clinical effects of existing glioma radiotherapy and chemotherapy.

[0007] In order to achieve the above-mentioned invention object, the present invention provides the following technical solutions: A stimulus-responsive nanocapsule for delivering PROTAC, which is a nanocapsule containing PROTAC drugs formed by cross-linking a polymer skeleton material under the action of a disulfide bond-containing cross-linker; The polymer skeleton material includes polyethylene glycol-polylysine-polyphenylalanine macromolecular polymer and tryptophan analog modified polyethylene glycol-polylysine-polyphenylalanine macromolecular polymer; The disulfide bond-containing cross-linking agent is a DTSSP cross-linking agent; The PROTAC drug is SIS or ARV-825.

[0008] Preferably, the chemical formula of the polyethylene glycol-polylysine-polyphenylalanine polymer is as shown in Formula I:

[0009] Formula I The chemical formula of the tryptophan analog modified polyethylene glycol-polylysine-polyphenylalanine high molecular polymer is as shown in Formula II:

[0010] Formula II Further preferably, the diameter of the nanocapsule is 100-110 nm; the zeta potential is 0-2 mV; the drug loading for SIS is 7.0% and the encapsulation efficiency is 67.89%.

[0011] The method for preparing the above-mentioned stimulus-responsive nanocapsule for delivering PROTAC comprises the following steps: (1) N 6-Benzyloxycarbonyl-L-lysine and triphosgene were mixed and protected with argon; then anhydrous tetrahydrofuran was added and reacted at 50 °C for 3 h; cooled to room temperature, insoluble matter was removed by filtration, and the filtrate was slowly dripped into pre-cooled anhydrous n-hexane, filtered, the product was collected, and vacuum dried to obtain Lys(Cbz)-NCA; (2) Weigh L-phenylalanine and triphosgene, mix them, and protect them with argon; then add anhydrous tetrahydrofuran and react at 50 °C for 3 h; cool to room temperature, filter to remove insoluble matter, and slowly drip the filtrate into pre-cooled anhydrous n-hexane, stir, filter, collect the product, and vacuum dry to obtain Phe-NCA; (3) CH3O-PEG112-NH2 and Lys(Cbz)-NCA were protected by argon; then anhydrous DMF was added and the mixture was reacted at 50°C for 48 hours to obtain reaction solution 1; Phe-NCA was dissolved in anhydrous DMF and added to the reaction solution 1 and the mixture was reacted at 50°C for 48 hours to obtain reaction solution 2; a DMF solution of acetic anhydride and triethylamine was added to the reaction solution 2 and the mixture was reacted at room temperature for 3 hours; after the reaction was terminated, the obtained solution was dialyzed in pure water for 24 hours; and the product mPEG was obtained after freeze drying. 112 -pLys(Cbz)-pPhe-CH3; (4) mPEG 112 -pLys(Cbz)-pPhe-CH3 was dissolved in trifluoroacetic acid under stirring, and then HBr solution was added and reacted at room temperature for 1.5 h; then, the reaction system was dialyzed and freeze-dried to collect the product mPEG 112 -pLys-pPhe-CH3; (5) Disperse 1-methyl-L-tryptophan in a mixed solution of pure water and tetrahydrofuran, add NaOH, stir to dissolve, drop (Boc)2O, react at 0°C for 10 min, and react at 25°C for 24 h; evaporate the solvent to obtain a reaction mixture; acidify the reaction mixture with hydrochloric acid until the solid no longer increases; extract the reaction mixture with ethyl acetate; dry the organic layer with anhydrous Na2SO4; evaporate the organic solvent; and dry in vacuo to obtain the product Boc-N-1-methyl-L-tryptophan (MLT-Boc); (6) MLT-Boc, 1-hydroxybenzotriazole (HOBT), and benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU) were activated in anhydrous DMF in an ice bath under argon protection for 40 min; then propargylamine and DMF solution of N,N-diisopropylethylamine (DIPEA) were added, the temperature was gradually restored to room temperature, and the reaction was carried out for 24 h; the product 1-MLT(Boc)-propargyl was separated under column chromatography conditions with a mobile phase of dichloromethane / ethyl acetate in a volume ratio of 90 / 10; (7) Dissolve N3-PEG112-NH2 and 1-MLT(Boc)-propargyl in anhydrous DMF, then add DMF solution of CuI and DIPEA, protect with high-purity argon, and finally add sodium ascorbate (VcNa); react at room temperature overnight in the dark. After the reaction, place the reaction solution in a dialysis bag and dialyze it in a PBS solution containing 10 mM EDTA-2Na at pH 7.4 for 24 h until the red color of the system disappears and turns yellow. Then transfer the dialysis bag to pure water for 24 h and freeze-dry to obtain a light yellow product MLT-Boc-PEG 112 -NH2; (8) MLT-Boc-PEG 112 -NH2 and Lys(Cbz)-NCA were dissolved in anhydrous DMF under the protection of high-purity argon and reacted at 50°C for 48 h. Then, they were added to the DMF solution of Phe-NCA and reacted at 50°C for 48 h. The product MLT-Boc-PEG was precipitated with cold ether. 112 -pLys(Cbz)-pPhe-NH2; (9) MLT-Boc-PEG 112 -pLys (Cbz)-pPhe-NH2 was dissolved in trifluoroacetic acid, HBr was added, and the mixture was stirred at room temperature for 1.5 h. The reaction system was dialyzed and freeze-dried to obtain a light yellow product, MLT-PEG 112 -pLys-pPhe-NH2; (10) Preparation of nanocapsules by nanoprecipitation method: mPEG was prepared at a concentration of 20 mg / mL. 112 -pLys-pPhe-CH3, MLT-PEG 112 - DMSO solution of pLys-pPhe-NH2 material and SIS drug; take mPEG 112 -pLys-pPhe-CH3 DMSO solution, MLT-PEG 112 -pLys-pPhe-NH2 DMSO solution and SIS DMSO solution were mixed; then added dropwise into pure water; stirred for 4 hours; dialyzed for 12 hours to remove DMSO, and the water was changed every 4 hours to obtain MPLP@SIS nanoparticles; DTSSP solution was added to the MPLP@SIS nanoparticle preparation, reacted at room temperature for 6 hours, and dialyzed with pure water for 12 hours to remove excess DTSSP, and MPL was obtained. (SS) P@SIS nanocapsules.

[0012] Preferably, in step (1), N 6 The molar ratio of -benzyloxycarbonyl-L-lysine to triphosgene is 2.5:1.

[0013] Preferably, the molar ratio of L-phenylalanine to triphosgene in step (2) is 2:1.

[0014] Preferably, in step (3), the molar ratio of Lys(Cbz)-NCA, Phe-NCA and CH3O-PEG-NH2 is 12:20:1; the molar ratio of acetic anhydride, triethylamine and CH3O-PEG-NH2 is 5:3:1.

[0015] Preferably, in step (4), 200 mg of the mPEG 112 The solid of -pLys(Cbz)-pPhe-CH3 was dissolved by adding 10 mL of trifluoroacetic acid, and then 200 µL of HBr was added for reaction, wherein the HBr was a 33 wt.% acetic acid solution.

[0016] Preferably, in step (5), the volume ratio of pure water to tetrahydrofuran is 1:1, and the amounts of reactants are: 400 mg of 1-methyl-L-tryptophan, 350 µL of (Boc)2O; the concentration of NaOH is 1 mol / L; and the concentration of hydrochloric acid is 1 mol / L.

[0017] Preferably, in step (6), HOBT and HBTU are used as amide condensation agents to promote the amide reaction; DIPEA is a basic organic catalyst for the condensation reaction; the molar ratio of MLT-Boc to propargylamine is 1:1.2; and the molar ratio of MLT-Boc to HOBT, HBTU, and DIPEA is 1:1.1:1.1:2.4.

[0018] Preferably, in step (7), the molar ratio of N3-PEG112-NH2 to 1-MLT(Boc)-propargyl is 1:2; the molar ratio of N3-PEG112-NH2 to CuI, DIPEA, and VcNa is 1:1:1:15; CuI plays a catalytic role; the role of excess VcNa is to prevent CuI oxidation; EDTA-2Na removes excess copper ions by complexation during dialysis; the obtained product MLT-Boc-PEG 112 -NH2 is light yellow.

[0019] Preferably, in step (8), Lys (Cbz)-NCA, Phe-NCA and MLT-Boc-PEG 112 The molar ratio of -NH2 is 12:20:1.

[0020] Preferably, in step (9), 200 mg MLT-PEG 112The solid of -pLys(Cbz)-pPhe-NH2 was dissolved by adding 10 mL of trifluoroacetic acid, and 200 µL of HBr was added for reaction, wherein the HBr was a 33 wt.% acetic acid solution.

[0021] Preferably, the mPEG in step (10) 112 -pLys-pPhe-CH3, MLT-PEG 112 The mass ratio of -pLys-pPhe-NH2 and SIS was 9:1:1; the solvent of DTSSP solution was PBS with pH 12.1, the concentration of DTSSP solution was 20 mg / mL, 100 μL DTSSP solution was added to 1 mL of nanoparticle preparation, reacted for 6 h, and dialyzed for 12 h to remove excess DTSSP to obtain MPL. (SS) P@SIS nanocapsules.

[0022] The above-mentioned stimulus-responsive nanocapsule for delivering PROTAC is used in the treatment of glioma drugs.

[0023] The dialysis method is as follows: placing the product in a dialysis bag with a molecular weight cutoff of 3500, immersing the bag in water, and dialyzing to remove impurities.

[0024] The room temperature in the present invention refers to 25°C.

[0025] Compared with the prior art, the beneficial effects of the present invention include: (1) The nanocapsule carrier of the present invention does not produce obvious toxicity to the body and has good biocompatibility; (2) The nanocapsules prepared by the present invention have a small particle size and uniform morphology, and the capsule skeleton can react with GSH to have lesion responsiveness and release drugs; (3) The nanocapsules prepared by the present invention can be used as nanomedicines for the treatment of gliomas and are suitable for intravascular injection. The nanocapsules can target L-type amino acid transporter 1 with the help of tryptophan analogs and cross the blood-brain barrier to be enriched in glioma lesions. Under the stimulation of high concentrations of glutathione in glioma lesions, the nanocapsules selectively release PROTAC drugs to degrade target proteins. At the same time, the nanocapsule carriers enhance the level of reactive oxygen species and can enhance DNA damage. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1 The non-targeted high molecular weight polymer mPEG in Example 1 112 -The synthetic route of pLys-pPhe-CH3; Figure 2 The targeted high molecular weight polymer MLT-PEG in Example 1 112 -The synthetic route of pLys-pPhe-NH2; Figure 3 mPEG 112 -NMR hydrogen spectrum of pLys-pPhe-CH3; Figure 4 MLT-PEG 112 -NMR hydrogen spectrum of pLys-pPhe-NH2; Figure 5 Schematic diagram of the preparation of targeted nanocapsules in Example 1; Figure 6 is the dynamic light scattering particle size distribution of the targeted nanocapsules of Example 1; Figure 7 is the potential distribution of the targeted nanocapsule of Example 1; Figure 8 The transmission electron microscope morphology image of the targeted nanocapsule of Example 1; Fig. 9 The drug release curves of the non-targeted nanoparticles and nanocapsules in the PBS system of Example 1; Fig.10 The drug release curve of the targeted nanocapsule of Example 1 under the stimulation of different concentrations of DTT; Fig.11 The degradation effect of the targeted nanocapsules of Example 1 on the target protein BRD4 in glioma cells G422 at different concentrations; Fig.12 The inhibitory effect of the targeted nanocapsule carrier of Example 1 on glioma cells G422 at different concentrations; Fig.13 The effect of different drug administration groups on the survival rate of GBM model mice in Example 1; Fig.14 The effect of different drug administration groups on the body weight of GBM model mice in Example 1; G1: normal saline group; G2: MPL (SS) P@SIS nanocapsule group; G3: X-ray + TMZ group; G4: MPL (SS) P@SIS nanocapsule + TMZ group; G5: MPL (SS) P@SIS nanocapsule + X-ray group; G6: PL (SS) P@SIS non-targeted nanocapsule + X-ray + TMZ group; G7: MPL (SS) P@SIS nanocapsule + X-ray + TMZ group. DETAILED DESCRIPTION

[0027] The present invention will be further described below in conjunction with specific embodiments, and the advantages and features of the present invention will become clearer as the description proceeds. However, the embodiments are exemplary only and do not constitute any limitation to the scope of the present invention. It should be understood by those skilled in the art that the details and forms of the technical solution of the present invention may be modified or replaced without departing from the spirit and scope of the present invention, but these modifications and replacements all fall within the scope of protection of the present invention.

[0028] Example 1 A method for preparing a stimuli-responsive nanocapsule for delivering PROTAC comprises the following steps: (1) High molecular weight polymer mPEG 112 Synthesis of -pLys-pPhe-CH3 according to Figure 1 The synthetic route is synthesized in sequence: a. Synthesis of Lys(Cbz)-NCA 3 g N 6 -Benzyloxycarbonyl-L-lysine (10.71 mmol, 1 equiv.), 1.27 g triphosgene (4.28 mmol, 0.4 equiv.) were placed in a 100 mL two-necked bottle, and the gas in the bottle was replaced with an argon balloon. After that, 50 mL of anhydrous tetrahydrofuran was added to the two-necked bottle with a syringe while stirring. At this time, the system was a white turbid liquid, and it was transferred to a 50 ℃ oil bath for reaction for 3 h. After the reaction was completed, the system turned into a colorless transparent solution, which was cooled to room temperature and filtered to remove the remaining insoluble matter. Then, a plastic dropper was used to slowly drop the reaction solution into a beaker containing 500 mL pre-cooled (-20 ℃) ​​anhydrous n-hexane. During the dropwise addition, the system was stirred with a stirrer to fully precipitate, and then a white solid was obtained by suction filtration. It was washed with a small amount of n-hexane, compacted and dried overnight. After it was completely dried, it was taken out and weighed, the yield was calculated, and hydrogen spectrum characterization was performed.

[0029] b. Synthesis of Phe-NCA Weigh 3 g L-phenylalanine (18.16 mmol, 1 equiv.) and 2.7 g triphosgene (9.10 mmol, 0.5 equiv.) in a 100 mL two-necked bottle, and replace the gas in the bottle with an argon balloon. Then, use a syringe to add 60 mL of anhydrous tetrahydrofuran to the two-necked bottle while stirring. At this time, the system is a white turbid liquid, and it is transferred to a 50°C oil bath for reaction for 3 h. After the reaction is completed, the system turns into a colorless and transparent solution, which is placed at room temperature and filtered to remove the remaining insoluble matter. Then, use a plastic dropper to slowly drop the reaction solution into a beaker containing 600 mL pre-cooled (-20°C) anhydrous n-hexane. During the dropwise addition, use a stirrer to stir the system to fully precipitate the flocculent precipitate, then filter to obtain a white solid, wash it with n-hexane, compact it and dry it. After it is completely dried, take it out and weigh it, calculate the yield, and perform hydrogen spectrum characterization.

[0030] c.mPEG 112 Synthesis of -pLys(Cbz)-pPhe-CH3 Weigh 200 mg CH3O-PEG112-NH2 (0.04 mmol, 1 equiv.) and 148 mg Lys(Cbz)-NCA (0.48 mmol, 12 equiv.) into a 100 mL two-necked flask, and replace the gas in the flask with argon. Afterwards, 20 mL of anhydrous DMF was added to the two-necked flask with a syringe while stirring. At this time, the system turned into a colorless and transparent solution and was transferred to a 50 ℃ oil bath for reaction for 48 h; 153 mg of compound Phe-NCA (0.8 mmol, 20 equiv.) was dissolved in anhydrous DMF and then injected into a 100 mL two-necked flask. At this time, the system turned into a colorless and transparent solution and reacted in a 50 ℃ oil bath for 48 h; 20 μL of acetic anhydride (0.20 mmol, 21 mg, 5 equiv.) and 17.5 μL of triethylamine (0.12 mmol, 13 mg, 3 equiv) were added and reacted at room temperature for 3 h. After the reaction was terminated, the above solution was drawn into a dialysis bag and dialyzed in a large volume of pure water for 24 h (the water was changed 3 times at equal time intervals). Afterwards, the suspension in the dialysis bag was drawn into a plastic tube and freeze-dried to obtain a white powder solid. Weigh to calculate the yield and perform hydrogen spectrum characterization.

[0031] d. mPEG 112 Synthesis of -pLys-pPhe-CH3 Weigh 200 mg mPEG 112-pLys(Cbz)-pPhe-CH3 was placed in a single-mouth bottle, and 10 mL of trifluoroacetic acid was added under stirring to dissolve the polymer. At this time, the system was a light yellow solution. Then, 200 μL of HBr (33 wt.%, acetic acid solution) was added. At this time, a large amount of carbon dioxide gas was generated, and the yellow color of the system deepened. The bottle mouth was sealed with a glass stopper and stirred at room temperature for 1.5 hours. After that, the reaction system was dialyzed and a white powder solid was obtained after freeze-drying. The yield was calculated by weighing and identified by hydrogen spectrum. The results are as follows Figure 3 as shown in .

[0032] (2) Targeted polymer MLT-PEG 112 Synthesis of -pLys-pPhe-NH2 according to Figure 2 The synthetic route is synthesized in sequence: a. Synthesis of Boc-N-1-methyl-L-tryptophan Suspend 400 mg of 1-methyl-L-tryptophan in a system of pure water: tetrahydrofuran = 1:1, add 6 mL of 1 mol / L NaOH, stir to dissolve, drop 350 µL of (Boc)2O, react at 0 °C for 10 min and at 25 °C for 24 h; evaporate the solvent, cool the residue in an ice bath, acidify the reaction mixture with 1 mol / L hydrochloric acid solution until the solid no longer increases; extract the reaction mixture with ethyl acetate; dry the organic layer with anhydrous Na2SO4; evaporate the solvent; and dry in vacuum to obtain Boc-N-1-methyl-L-tryptophan.

[0033] b. Synthesis of 1-MLT(Boc)-propargyl MLT-Boc (100 mg), HOBT (42.6 mg), HBTU (119.2 mg) were placed in a two-necked bottle, 10 mL of anhydrous DMF was added at once, and the mixture was activated in an ice bath for 40 min; propargylamine (19 mg) and DIPEA (89 mg) were dissolved in anhydrous DMF and added to the system, the ice bath was removed, and the mixture was gradually restored to room temperature and reacted for 24 h; the product 1-MLT(Boc)-propargyl was separated under the condition of dichloromethane / ethyl acetate = 90 / 10 as the mobile phase.

[0034] c. MLT-Boc-PEG 112 Synthesis of -NH2 Weigh 102 mg N3-PEG112-NH2 and 14.5 mg 1-MLT(Boc)-propargyl in a 50 mL two-necked flask, add 2 mL of anhydrous DMF solution, dissolve CuI (3.8 mg) and DIPEA (2.59 mg) in anhydrous DMF solution; add DIPEA and CuI, protect with high-purity argon, and finally add 59.4 mg VcNa; react at room temperature overnight (12 h) in the dark. After the reaction, put the reaction solution into a dialysis bag and dialyze it in 5 L of PBS (pH 7.4) solution containing 10 mM EDTA-2Na for 24 h until the red color of the system disappears and turns into a very weak yellow color. Then transfer the dialysis bag to pure water for 24 h and freeze-dry to obtain a light yellow product MLT-Boc-PEG 112 -NH2.

[0035] d. MLT-Boc-PEG 112 Synthesis of -pLys(Cbz)-pPhe-NH2 Weigh 200 mg MLT-Boc-PEG 112 -NH2 (0.04 mmol, 1 equiv.), 148 mg Lys(Cbz)-NCA (0.48 mmol, 12 equiv.) were placed in a two-necked flask and isolated from the air by high-purity argon; 20 mL of anhydrous DMF was added and the mixture was reacted in an oil bath at 50 °C for 48 h; 153 mg Phe-NCA (0.80 mmol, 20 equiv.) was dissolved in 20 mL of anhydrous DMF and added to the system and reacted at 50 °C for 48 h; the product MLT-Boc-PEG was obtained by cold ether precipitation. 112 -pLys(Cbz)-pPhe-NH2.

[0036] e. MLT-PEG 112 Synthesis of -pLys-pPhe-NH2 Weigh 200 mg MLT-Boc-PEG 112 -pLys (Cbz)-pPhe-CH3 was placed in a single-mouth bottle, and 10 mL of trifluoroacetic acid was added under stirring to dissolve the polymer. At this time, the system was a light yellow solution; 200 μL of HBr (33 wt.%, acetic acid solution) was added, and a large amount of carbon dioxide gas was generated, and the yellow color of the system deepened. The bottle mouth was sealed with a glass stopper and stirred at room temperature for 1.5 h; the reaction system was dialyzed and freeze-dried to obtain the product MLT-PEG 112 -pLys-pPhe-NH2, and the results were analyzed by H NMR. Figure 4 as shown in .

[0037] (3) Preparation of nanocapsules by nanoprecipitation method according to Figure 5 Preparation of nanocapsules a. Preparation of MPLP@SIS nanoparticles mPEG 112 -pLys-pPhe-CH3, MLT-PEG 112 - pLys-pPhe-NH2 material and SIS drug were dissolved in DMSO to a concentration of 20 mg / mL; 180 µL of mPEG was taken. 112 -pLys-pPhe-CH3 DMSO solution, 20 µL of MLT-PEG 112 -pLys-pPhe-NH2 DMSO solution and 20 μL SIS DMSO solution were mixed; the mixed DMSO solution was added dropwise into 1.8 mL pure water; stirred for 4 hours; dialyzed with pure water for 12 hours to remove DMSO, and the water was changed every 4 hours. MPLP@SIS nanoparticles were obtained.

[0038] b. MPL (SS) Preparation of P@SIS nanocapsules DTSSP was dissolved in PBS at pH 12.1 to a concentration of 20 mg / mL. 1 mL of nanoparticle preparation was added with 100 µL of DTSSP solution, reacted for 6 h, and dialyzed for 12 h to remove excess DTSSP to obtain MPL. (SS) P@SIS nanocapsules.

[0039] The nanocapsules were subjected to the following tests: Figure 6 is the dynamic light scattering particle size of PROTAC nanocapsules; visible: MPL (SS) The particle size of P@SIS nanocapsules is about 100 nm, which is significantly reduced compared with nanoparticles.

[0040] Figure 7 The zeta potential distribution of PROTAC nanocapsules. It can be seen that the zeta potential of MPLP@SIS nanoparticles is about 25mV, and the zeta potential of MPL (SS) The zeta potential of P@SIS nanocapsules is about 2mV, which is significantly lower than that of nanoparticles.

[0041] Figure 8 This is the transmission electron microscopy morphology of PROTAC nanocapsules; it can be seen that the nanoparticles are nearly spherical, with uniform morphology and a particle size of about 100nm.

[0042] Preparation of non-targeted nanocapsules for studying drug release characteristics a. Preparation of PLP@SIS nanoparticles Dissolve the mPEG112-pLys-pPhe-CH3 material and SIS drug in DMSO to a concentration of 20 mg / mL; mix 200 µL of DMSO solution containing mPEG112-pLys-pPhe-CH3 and 20 µL of DMSO solution containing SIS; add the mixed DMSO solution dropwise into 1.8 mL of pure water; stir for 4 hours; dialyze the pure water for 12 hours to remove DMSO, and change the water every 4 hours. PLP@SIS nanoparticles are obtained.

[0043] b. Preparation of PL(SS)P@SIS nanocapsules DTSSP was dissolved in PBS at pH 12.1 to a concentration of 20 mg / mL. 100 μL of DTSSP solution was added to 1 mL of the nanoparticle preparation, reacted for 6 h, and dialyzed for 12 h to remove excess DTSSP to obtain PL(SS)P@SIS nanocapsules.

[0044] Fig. 9 Drug release curves of nanoparticles and nanocapsules in PBS system; the release amount of nanocapsules in PBS system is 30% in 12 hours. Compared with nanoparticles, cross-linking gives nanocapsules stronger stability.

[0045] Fig.10 The figure shows the drug release curve of PROTAC nanocapsules under the stimulation of different concentrations of DTT. 10mM DTT simulates the state of high GSH in the tumor area. It can be seen that over time, the nanocapsules release more and more PROTAC drugs SIS under the stimulation of DTT, and high concentration DTT can significantly promote the release of SIS drugs from the nanocapsules.

[0046] Fig.11 The degradation effect of nanocapsules on the target protein BRD4 in glioma cells G422 at different concentrations; MPL (SS) P@SIS nanocapsules can effectively degrade the target protein BRD4, with the strongest degradation effect at a concentration of 100nM.

[0047] Fig.12 The inhibitory effect of nanocapsule carriers on glioma cells G422 at different concentrations; it can be seen that the nanocapsule carriers have no obvious toxicity to cells even at a concentration of 250µg / mL, indicating that the nanocapsule carriers themselves will not cause obvious toxicity to the body and have good biocompatibility.

[0048] Fig.13 Effects of different drug administration groups on the survival rate of GBM model mice; visible: Nanocapsule MPL (SS)P@SIS combined with X-ray radiotherapy and TMZ chemotherapy had the highest survival rate, indicating that nanocapsules are beneficial to the therapeutic effect of radiotherapy and chemotherapy on glioma.

[0049] Fig.14 Effects of different dosing groups on the body weight of GBM model mice; visible: Nanocapsule MPL (SS) P@SIS combined with X-ray radiotherapy and TMZ chemotherapy had the slightest weight loss effect, indicating that the nanocapsules were beneficial to the therapeutic effect of radiotherapy and chemotherapy on glioma.

[0050] Example 2 A method for preparing a stimuli-responsive nanocapsule for delivering PROTAC drug ARV-825 comprises the following steps: (1) Preparation of ARV-825-loaded nanoparticles mPEG 112 -pLys-pPhe-CH3, MLT-PEG 112 - pLys-pPhe-NH2 material and ARV-825 drug were dissolved in DMSO to a concentration of 20 mg / mL; 180 µL of mPEG was taken 112 -pLys-pPhe-CH3 DMSO solution, 20 µL of MLT-PEG 112 -pLys-pPhe-NH2 DMSO solution and 20 µL DMSO solution containing ARV-825 were mixed; the mixed DMSO solution was added dropwise into 1.8 mL pure water; stirred for 4 hours; dialyzed with pure water for 12 hours to remove DMSO, and the water was changed every 4 hours. MPLP@ARV nanoparticles with targeting function were obtained.

[0051] (2) Preparation of nanocapsules containing ARV-825 DTSSP was dissolved in PBS at pH 12.1 to a concentration of 20 mg / mL. 1 mL of nanoparticle preparation was added with 100 µL of DTSSP solution, reacted for 6 h, and dialyzed for 12 h to remove excess DTSSP. MPL with brain targeting function was obtained. (SS) P@ARV nanocapsules.

[0052] (3) Characterization of MPL (SS) P@ARV nanocapsules MPL (SS) The particle size of P@ARV nanocapsules is about 110nm, the zeta potential is about 0-5mV, the drug loading capacity of ARV-825 is about 5.0%, and the encapsulation efficiency is about 52.3%.

Claims

1. A stimuli-responsive nanocapsule for delivering PROTAC, characterized in that: It is a nanocapsule containing PROTAC drugs formed by cross-linking a polymer skeleton material under the action of a disulfide bond-containing cross-linker; The polymer skeleton material includes polyethylene glycol-polylysine-polyphenylalanine macromolecular polymer and tryptophan analog modified polyethylene glycol-polylysine-polyphenylalanine macromolecular polymer; The disulfide bond-containing cross-linking agent is a DTSSP cross-linking agent; The PROTAC drug is SIS or ARV-825.

2. A stimulus-responsive nanocapsule for delivering PROTAC according to claim 1, characterized in that: The chemical formula of the polyethylene glycol-polylysine-polyphenylalanine polymer is as shown in Formula I: Formula I The chemical formula of the tryptophan analog modified polyethylene glycol-polylysine-polyphenylalanine high molecular polymer is as shown in Formula II: Formula II Preferably, the diameter of the nanocapsule is 100-110 nm; the zeta potential is 0-2 mV; the drug loading for SIS is 7.0% and the encapsulation efficiency is 67.89%.

3. A method for preparing a stimulus-responsive nanocapsule for delivering PROTAC according to claim 1 or 2, characterized in that: The following steps are involved: (1) N 6 -Benzyloxycarbonyl-L-lysine and triphosgene were mixed and protected with argon; then anhydrous tetrahydrofuran was added and reacted at 50 °C for 3 h; cooled to room temperature, insoluble matter was removed by filtration, and the filtrate was slowly dripped into pre-cooled anhydrous n-hexane, filtered, the product was collected, and vacuum dried to obtain Lys(Cbz)-NCA; (2) Weigh L-phenylalanine and triphosgene, mix them, and protect them with argon; then add anhydrous tetrahydrofuran and react at 50 °C for 3 h; cool to room temperature, filter to remove insoluble matter, and slowly drip the filtrate into pre-cooled anhydrous n-hexane, stir, filter, collect the product, and vacuum dry to obtain Phe-NCA; (3) CH3O-PEG112-NH2 and Lys(Cbz)-NCA were protected by argon; then anhydrous DMF was added and the mixture was reacted at 50°C for 48 hours to obtain reaction solution 1; Phe-NCA was dissolved in anhydrous DMF and added to the reaction solution 1 and the mixture was reacted at 50°C for 48 hours to obtain reaction solution 2; a DMF solution of acetic anhydride and triethylamine was added to the reaction solution 2 and the mixture was reacted at room temperature for 3 hours; after the reaction was terminated, the obtained solution was dialyzed in pure water for 24 hours; and the product mPEG was obtained after freeze drying. 112 -pLys(Cbz)-pPhe-CH3; (4) mPEG 112 -pLys(Cbz)-pPhe-CH3 was dissolved in trifluoroacetic acid under stirring, and then HBr solution was added and reacted at room temperature for 1.5 h; then, the reaction system was dialyzed and freeze-dried to collect the product mPEG 112 -pLys-pPhe-CH3; (5) Disperse 1-methyl-L-tryptophan in a mixed solution of pure water and tetrahydrofuran, add NaOH, stir to dissolve, drop (Boc)2O, react at 0°C for 10 min, and react at 25°C for 24 h; evaporate the solvent to obtain a reaction mixture; acidify the reaction mixture with hydrochloric acid until the solid no longer increases; extract the reaction mixture with ethyl acetate; dry the organic layer with anhydrous Na2SO4; evaporate the organic solvent; and dry in vacuo to obtain the product Boc-N-1-methyl-L-tryptophan (MLT-Boc); (6) MLT-Boc, 1-hydroxybenzotriazole (HOBT), and benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU) were activated in anhydrous DMF in an ice bath under argon protection for 40 min; then propargylamine and DMF solution of N,N-diisopropylethylamine (DIPEA) were added, the temperature was gradually restored to room temperature, and the reaction was carried out for 24 h; the product 1-MLT(Boc)-propargyl was separated under column chromatography conditions with a mobile phase of dichloromethane / ethyl acetate in a volume ratio of 90 / 10; (7) Dissolve N3-PEG112-NH2 and 1-MLT(Boc)-propargyl in anhydrous DMF, then add DMF solution of CuI and DIPEA, protect with high-purity argon, and finally add sodium ascorbate VcNa; react at room temperature overnight in the dark. After the reaction, put the reaction solution into a dialysis bag and dialyze it in a PBS solution containing 10 mM EDTA-2Na at pH 7.4 for 24 h until the red color of the system disappears and turns yellow. Then transfer the dialysis bag to pure water for dialysis for 24 h, and freeze-dry to obtain a light yellow product MLT-Boc-PEG 112 -NH2; (8) MLT-Boc-PEG 112 -NH2 and Lys(Cbz)-NCA were dissolved in anhydrous DMF under the protection of high-purity argon and reacted at 50 °C for 48 h. Then, they were added to the DMF solution of Phe-NCA and reacted at 50 °C for 48 h. The product MLT-Boc-PEG was precipitated with cold ether. 112 -pLys(Cbz)-pPhe-NH2; (9) MLT-Boc-PEG 112 -pLys (Cbz)-pPhe-NH2 was dissolved in trifluoroacetic acid, HBr was added, and the mixture was stirred at room temperature for 1.5 h. The reaction system was dialyzed and freeze-dried to obtain a light yellow product, MLT-PEG 112 -pLys-pPhe-NH2; (10) Preparation of nanocapsules by nanoprecipitation method: mPEG was prepared at a concentration of 20 mg / mL. 112 -pLys-pPhe-CH3, MLT-PEG 112 - DMSO solution of pLys-pPhe-NH2 material and SIS drug; take mPEG 112 -pLys-pPhe-CH3 DMSO solution, MLT-PEG 112 -pLys-pPhe-NH2 DMSO solution and SIS DMSO solution were mixed; then added dropwise into pure water; stirred for 4 hours; dialyzed for 12 hours to remove DMSO, and the water was changed every 4 hours to obtain MPLP@SIS nanoparticles; DTSSP solution was added to the MPLP@SIS nanoparticle preparation, reacted at room temperature for 6 hours, and dialyzed with pure water for 12 hours to remove excess DTSSP, and MPL was obtained. (SS) P@SIS nanocapsules.

4. A method for preparing a stimulus-responsive nanocapsule for delivering PROTAC according to claim 3, characterized in that: In step (1), N 6 - the molar ratio of benzyloxycarbonyl-L-lysine to triphosgene is 2.5:1; Preferably, the molar ratio of L-phenylalanine to triphosgene in step (2) is 2:1; Preferably, in step (3), the molar ratio of Lys(Cbz)-NCA, Phe-NCA and CH3O-PEG-NH2 is 12:20:1; the molar ratio of acetic anhydride, triethylamine and CH3O-PEG-NH2 is 5:3:

1.

5. A method for preparing a stimulus-responsive nanocapsule for delivering PROTAC according to claim 3, characterized in that: In step (4), 200 mg of the mPEG 112 -pLys(Cbz)-pPhe-CH3 solid is dissolved by adding 10 mL trifluoroacetic acid, and then 200 µL HBr is added for reaction, wherein the HBr is a 33 wt.% acetic acid solution; preferably, in step (5), the volume ratio of pure water to tetrahydrofuran is 1:1, and the amount of reactants is: 400 mg of 1-methyl-L-tryptophan, 350 µL of (Boc)2O; the concentration of NaOH is 1 mol / L; and the concentration of hydrochloric acid is 1 mol / L.

6. A method for preparing a stimulus-responsive nanocapsule for delivering PROTAC according to claim 3, characterized in that: In step (6), the molar ratio of MLT-Boc to propargylamine is 1:1.2; the molar ratio of MLT-Boc to HOBT, HBTU, and DIPEA is 1:1.1:1.1:2.4; Preferably, in step (7), the molar ratio of N3-PEG112-NH2 to 1-MLT(Boc)-propargyl is 1:2; the molar ratio of N3-PEG112-NH2 to CuI, DIPEA, and VcNa is 1:1:1:

15.

7. A method for preparing a stimulus-responsive nanocapsule for delivering PROTAC according to claim 3, characterized in that: Lys(Cbz)-NCA, Phe-NCA and MLT-Boc-PEG described in step (8) 112 The molar ratio of -NH2 is 12:20:

1.

8. A method for preparing a stimulus-responsive nanocapsule for delivering PROTAC according to claim 3, characterized in that: In step (9), 200 mg MLT-PEG 112 The solid of -pLys(Cbz)-pPhe-NH2 was dissolved by adding 10 mL of trifluoroacetic acid, and 200 µL of HBr was added for reaction, wherein the HBr was a 33 wt.% acetic acid solution.

9. A method for preparing a stimulus-responsive nanocapsule for delivering PROTAC according to claim 3, characterized in that: mPEG described in step (10) 112 -pLys-pPhe-CH3, MLT-PEG 112 The mass ratio of -pLys-pPhe-NH2 and SIS was 9:1:1; the solvent of DTSSP solution was PBS with pH 12.1, the concentration of DTSSP solution was 20 mg / mL, 100 μL DTSSP solution was added to 1 mL of nanoparticle preparation, reacted for 6 h, and dialyzed for 12 h to remove excess DTSSP to obtain MPL. (SS) P@SIS nanocapsules.

10. Use of a stimulus-responsive nanocapsule for delivering PROTAC according to claim 1 or 2 in a drug for treating glioma.

Citation Information

Patent Citations

  • Micellar drug delivery system with pH response charge overturning and hypoxia response drug release and preparation method of micelle drug delivery system

    CN115429755A

  • Stimulus-responsive nanogel based on prodrug and preparation method thereof

    CN115919748A

  • Hypoxia response drug delivery micelle adaptive to pancreatic cancer microenvironment and preparation method of hypoxia response drug delivery micelle

    CN116509801A

  • Targeted protein degradation chimera molecule self-assembly nano material as well as preparation method and application thereof

    CN118203646A

  • Gemcitabine nano prodrug with stable circulation as well as preparation method and application of gemcitabine nano prodrug

    CN118459755A